ArticleInjury epidemiology2026
Excess risk of fracture in incident Parkinson's disease Medicare beneficiaries.
Article in Injury epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundParkinson's disease (PD) is the second most common neurodegenerative disease, characterized by both motor and non-motor symptoms. Falls and fractures are common in advanced PD but the risk of fractures in newly diagnosed people with PD and the impact of treatment with levodopa is understudied.
methodsWe investigated the risk of fractures among Medicare beneficiaries with incident PD age ≥ 67 compared to controls. Among PD cases only with continuous Part D medication coverage, we examined the effect of levodopa treatment on fracture risk. We identified incident PD cases (N = 68,150) within a population-based sample of 2017 Medicare beneficiaries. Controls (N = 272,600) were matched 4:1 on age, sex, and month/year of the date of PD diagnosis. We used claims data from 2017-2019 to follow cases and controls to identify new fractures. Our primary outcome was any fracture. We classified fractures secondarily by body region (spine/vertebral, torso, pelvis, upper extremity, lower extremity [and separately hip]). We used competing risks regression models to estimate subhazard ratios (SHR) and 95% confidence intervals (CI) for the association between fracture and PD after adjusting for covariates. Among PD cases with continuous medication coverage (N = 61,317), we examined the effect of levodopa treatment in PD cases ever prescribed levodopa for 90 days (≥ 1 prescription fill).
resultsFollowing PD diagnosis/control reference date, the most common fracture location in incident PD cases and controls was in the hip, followed by the spine. PD cases had a greater risk of any fracture in all body regions compared to controls at any given time: any fracture (SHR 1.35, 95% CI 1.31-1.39), spine (SHR 1.47, 95% CI 1.35-1.59), hip (SHR 1.36, 95% CI 1.30-1.44), and upper extremity (SHR 1.34, 95% CI 1.22-1.48). PD cases who used levodopa for 90 days had a lower risk of any fracture (SHR 0.76, 95% CI 0.72-0.81) than those without treatment. This was also true for individual fracture types in all body regions with the exception of the torso and pelvis.
conclusionMedicare beneficiaries with incident PD have a greater risk of fracture in all body regions compared to controls and this risk may be reduced with levodopa use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.